CD8A and neoplasm: However, depletion of CD8+ T cells prevented muPD1-IL2v from achieving tumour growth inhibition when compared with muPD1-IL2v-treated mice that were not depleted of CD8+ T cells (Extended Data Fig. 7c,d), demonstrating that CD8+ T cells are indeed required for the efficacy observed under muPD1-IL2v therapy.